Internal
Contributions
Type: Publication Only
Background
Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. MPNs are acquired prothrombogenic conditions. The mechanism of increased predisposition to thrombosis in myeloproliferative neoplasms is not clear enough. Elevated leukocyte count is an independent prognostic factor for the development of thrombosis. It is considered that activated neutrophils bind platelets influencing the increased expression of tissue factor and activation and damage of endothelial cells, especially in JAK2V617F-positive patients.
Aims
The aim of this paper is to monitor the leukocyte count as a potential risk factor for the development of thrombotic complications with patients with Philadelphia-negative Chronic Myeloproliferative Neoplasms.
Methods
During the five-year period we followed up the occurrence of thrombotic complications and the leukocyte count in 109 patients of both sexes aged between 30 and 78 years, with a diagnosis of Ph-myeloproliferative neoplasms. Patients were classified into the following groups: 1. Group with Polycythemia Vera (PV) (51); 2. Group with Essential Thrombocythemia (ET) (28); 3. Group with Idiopathic Myelofibrosis (IMF) (21); 4. Group with myeloproliferative neoplasm unclassified (MPNs) (29). We used methods of clinical, laboratory, ultrasound and CT scans.
Results
The leukocyte count ranged from 2,2-17,1x109/L. The highest leukocyte count was recorded in the group of patients with PV and MPNs (p <0.001) and the lowest in the group of patients with the IMF (p <0.01). Between the group of patients with PV and MPNs there were not any statistically significant differences noticed in the leukocyte count. The highest percentage of thrombotic complications (arterial and venous) is in a group of patients with ET and MPNs (p <0.01) and then in the group with PV (p <0.05). Thrombotic complications in those groups were more frequent in percentage with patients with leukocytosis, but statistical significance was found only in the group with MPNs.
Summary
Leukocytosis may be considered as a potential risk factor for thrombosis in patients with myeloproliferative neoplasms, especially with PV, ET and MPNs. It is necessary to continue follow-up of these patients and to increase the number of subjects as well. Follow-up of the patients with neoplasms unclassified is of special importance, which showed a high prevalence of leukocytosis and thrombotic complications, and all with the aim to continue their further differentiation.
Keyword(s): Leukocytes, Myeloproliferative disorder, Thromboembolic events
Session topic: Publication Only
Type: Publication Only
Background
Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. MPNs are acquired prothrombogenic conditions. The mechanism of increased predisposition to thrombosis in myeloproliferative neoplasms is not clear enough. Elevated leukocyte count is an independent prognostic factor for the development of thrombosis. It is considered that activated neutrophils bind platelets influencing the increased expression of tissue factor and activation and damage of endothelial cells, especially in JAK2V617F-positive patients.
Aims
The aim of this paper is to monitor the leukocyte count as a potential risk factor for the development of thrombotic complications with patients with Philadelphia-negative Chronic Myeloproliferative Neoplasms.
Methods
During the five-year period we followed up the occurrence of thrombotic complications and the leukocyte count in 109 patients of both sexes aged between 30 and 78 years, with a diagnosis of Ph-myeloproliferative neoplasms. Patients were classified into the following groups: 1. Group with Polycythemia Vera (PV) (51); 2. Group with Essential Thrombocythemia (ET) (28); 3. Group with Idiopathic Myelofibrosis (IMF) (21); 4. Group with myeloproliferative neoplasm unclassified (MPNs) (29). We used methods of clinical, laboratory, ultrasound and CT scans.
Results
The leukocyte count ranged from 2,2-17,1x109/L. The highest leukocyte count was recorded in the group of patients with PV and MPNs (p <0.001) and the lowest in the group of patients with the IMF (p <0.01). Between the group of patients with PV and MPNs there were not any statistically significant differences noticed in the leukocyte count. The highest percentage of thrombotic complications (arterial and venous) is in a group of patients with ET and MPNs (p <0.01) and then in the group with PV (p <0.05). Thrombotic complications in those groups were more frequent in percentage with patients with leukocytosis, but statistical significance was found only in the group with MPNs.
Summary
Leukocytosis may be considered as a potential risk factor for thrombosis in patients with myeloproliferative neoplasms, especially with PV, ET and MPNs. It is necessary to continue follow-up of these patients and to increase the number of subjects as well. Follow-up of the patients with neoplasms unclassified is of special importance, which showed a high prevalence of leukocytosis and thrombotic complications, and all with the aim to continue their further differentiation.
Keyword(s): Leukocytes, Myeloproliferative disorder, Thromboembolic events
Session topic: Publication Only